Nephrospec Treatment CURESPEC LOGO ON W_edited.jpg
Curespec logo 1.png
 

ABOUT US

The Global CKD and Hypertension Pandemic affects 1.13 Billion people worldwide, inflicting death and suffering. 
Global healthcare costs are estimated at over $500 Billion (1) a year.

Hypertension is one of the main causes of CKD - costing Medicare, in the USA alone,
over $84 billion (2,3) a year.

The only current solution, Dialysis, dramatically reduces patients' quality-of-life

 – 5-year patient survival probability for all renal replacement therapy - 50.8% (4).


CureSpec was Founded in 2020.
Our first market-ready product, Nephrospec™ is intended for the interrelated treatment of: 

- CKD (Chronic Kidney Disease)

- Hypertension (High Blood Pressure)

NephroSpec - Saving lives & costs

NephroSpec promotes new blood vessel formation and restores damaged tissue

function by means of its patented ShockWave technology. 

We hold an Established, market-ready product, with a strong IP portfolio, which includes a granted U.S. patent,

a fully developed CE-Marked device & Promising preliminary clinical results.

 

CureSpec has an established Production facility, a Global distribution chain and an experienced management team. 

  1. https://www.cdc.gov/chronicdisease/programs-impact/pop/high-blood-pressure.htm

  2. https://www.cdc.gov/kidneydisease/basics.html

  3. Gaziano TA, Asaf B, S Anand, et.al. The global cost of non-optimal blood pressure. J  Hypertens. 2009

  4. Kramer A, Boenink R, Noordzij M, et al. The ERA-EDTA Registry Annual Report 2017 : a summary. 2020

 

Nephrospec    - a medical device manufactured by Curespec.

Nephrospec    - a safe, non-invasive shockwave device intended for the treatment of CKD and Hypertension

Nephrospec    - promotes new blood vessel formation and restores damaged tissue function through its patented technology

Nephrospec    - saves up to 80% of costs while easing suffering and needless loss of lives

Benefits include:

  • Complementary solution to optimal medical care for CKD and hypertension

  • Kidney function improvement in weeks

  • Outpatient treatment delays onset of dialysis

TM

TM

TM

TM

OUR PRODUCT

pre

Pre treatment

ARAS Kidney

post

Post Shockwave treatment

Curespec uses shockwave technology to produce a neovascularization affect on the kidneys.

CLINICAL

 

Our Team

Avner Spector_edited.jpg

Avner Spector

Founder, Active Chairman

Mr. Spector has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies in Israel and the US. He holds a B.Sc. Degree in Mechanical Engineering from Ben-Gurion-University of the Negev, Israel.

  • Grey LinkedIn Icon
rotem k_edited.jpg

Rotem Kaynan

CEO

Mr. Kaynan is a Biomedical Engineer, 2005 Technion – Israel Institute of Technology. More than 15 years of experience in Medical Devices, leading teams of clinical applications, sales & product management.

  • Grey LinkedIn Icon
op.jpg

Ophir Brandt

CFO

Mr. Brandt is a Certified Public Accountant (CPA) from the Bar-Ilan University, and holds an MBA degree from the Hebrew University. Mr. Brandt has over 10 years of experience in financial management, including as a CFO in the private sector and as a Senior Auditor at Ernst & Young (EY). 

  • Grey LinkedIn Icon
Alex_edited_edited.jpg

Alex Slutzker

VP Clinical, Cofounder

Dr. Slutzker (Ph.D) has 10 years of experience in the clinical diagnostics and medical device fields. He holds a doctorate in the fields of Molecular biology, biochemistry and microbiology from the Ben-Gurion-University of the Negev, Israel

  • Grey LinkedIn Icon
hag_edited_edited.jpg

Hagay Spector

R&D Director

Mr. Spector is an Electronics Engineer, (from 2009, HIT- Holon Institute of Technology). His major expertise is Product Development in all of its layers with wide knowledge in Shockwave systems and X-ray Vision. 

  • Grey LinkedIn Icon
yael shpilman.jpg

Yael Spielmann

RA Manager

Yael Spielmann has over 17 years of experience in the medical device industry, serving as a Regulatory Affairs expert, developing regulatory strategies and compiling submissions to regulatory bodies worldwide.

  • Grey LinkedIn Icon

Advisory Board

Lilach%20Lerman_edited.jpg

Lilach O. Lerman, MD, PhD

The Arthur M. and Gladys D. Gray Professor in Honor of Dr. Howard A. Andersen Professor of Medicine and Physiology Director, Reno- Vascular Research Laboratory Division of Nephrology and Hypertension Mayo Clinic

  • Grey LinkedIn Icon
Amir%20Lerman%2C%20M.D._edited.jpg

Amir Lerman, M.D.

Barbara Woodward Lips Professor 

Associate Chair, Cardiovascular  Medicine Director - Cardiovascular Research Center Consultant, Department of Cardiovascular Medicine Mayo Clinic

  • Grey LinkedIn Icon
 

Contact Us

Thanks for submitting!

  • Instagram
  • Facebook
  • LinkedIn